The litigation, pending in the U.S. District Court for the Northern District of California, alleges that Procept executives misled shareholders regarding the company's handpiece sales. While the firm had previously suggested sales were aligned with procedural usage, a February 25, 2026, earnings report revealed a disconnect. Management disclosed that handpiece sales had consistently outpaced procedures since early 2023, resulting in an accumulated surplus of over 10,000 units in the field.
Procept BioRobotics Faces Class Action Over Inventory Disclosures
Investors who purchased Procept BioRobotics shares between February 2024 and February 2026 have until September 22, 2026, to file as lead plaintiffs in a securities class action. The lawsuit follows revelations of a massive inventory glut that triggered an 18% slide in the company's stock price.
This inventory imbalance forced a sharp correction, with U.S. quarterly handpiece sales plummeting from 13,225 units to 9,400 units—a sequential drop of nearly 30%. The resulting revenue shortfall caused the company to miss its annual guidance by tens of millions of dollars. Following the announcement, Procept shares dropped from $27.84 to $22.69 over two trading days. Kahn Swick & Foti, LLC, which is representing the plaintiffs in Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, is currently soliciting investors who suffered substantial losses to join the action.
Comments (0)
No comments yet. Be the first!